CAR Technology and Its Application in Treatment of Multiple Myeloma--Review.
10.7534/j.issn.1009-2137.2016.01.054
- Author:
Tong LI
1
;
Hong-Tao WANG
1
;
Zhuo-Gang LIU
2
Author Information
1. Department of Hematology, China Medical University Shengjing Hospital, Shenyang 110021, Liaoning Province, China.
2. Department of Hematology, China Medical University Shengjing Hospital, Shenyang 110021, Liaoning Province, China. E-mail: liuzg@sj-hospital.org.
- Publication Type:Journal Article
- MeSH:
Genetic Therapy;
Humans;
Immunotherapy, Adoptive;
methods;
Multiple Myeloma;
therapy;
Receptors, Antigen, T-Cell;
T-Lymphocytes;
cytology
- From:
Journal of Experimental Hematology
2016;24(1):279-284
- CountryChina
- Language:Chinese
-
Abstract:
Multiple myeloma (MM) is a hematologic malignancy resulted from genetic mutations in the process of B lymphocyte differentiating into plasma cells, the chemotherapy is the main treatment method, especially with the development of proteasome inhibitors and other drugs, the overall survival rate of MM patients has improved greatly, but the chemoresistance is still an important reason for treatment failure. Chimeric antigen receptor (CAR)-modified T lymphocyte therapy is a new method for tumor adoptive immunotherapy. By means of genetic modification, T cells are able to identify the target antigen specifically, and to kill target cells without major histocompatibility complex (MHC) restriction, therefore the specific killing activity is conspicuous, which has got considerable attention by the public, and has made remarkable achievements particularly in the treatment of B-lineage leukemia and lymphoma, but no systematic literatures were reported in the field of multiple myeloma using CAR therapy. Therefore, this review summarizes the research results of different CAR target in vivo and in vitro experiments for multiple myeloma.
